[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aga Khan University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":715},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,52,75,107,156,178,208,238,262,284,310,328,358,379,415,452,487,517,541,566,588,612,642,666,690],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100591673","structural-heat-adaptation-and-education-in-rural-setting-100591673",false,"NCT06983483","Structural Heat Adaptation and Education in Rural Setting","Structural Heat Adaptation and Education in Rural Setting (SHAPES Trial)","SHAPES","Inclusion Criteria:\n\n* All households within the selected clusters who provide consent.\n\nExclusion Criteria:\n\n* Households planning to move away from the study site within the next 6 months\n* Individuals with severe mental or physical health conditions that preclude participation",true,"ALL",{"count":21,"type":22},7128,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to understand whether simple, low-cost interventions, such as improved home cooling, practical advice, and minor home modifications, can help protect people's health and quality of life during periods of extreme heat in rural, low-income villages of Matiari, Pakistan.\n\nKey Questions the Study Seeks to Answer:\n\n1. Can these interventions reduce heat-related health problems such as dizziness, headaches, and heatstroke and improve quality of life?\n2. Can they lower indoor temperatures and improve sleep quality, comfort, and daily functioning?\n\nTo answer these questions, researchers will compare communities where families receive heat-related support and information with similar communities that do not, to assess any differences in health and well-being. Endline venous blood sampling will be conducted for biobanking only.\n\nWhat Participants Can Expect:\n\n* Answer questions about their health, living conditions, and how they cope with heat\n* Have small temperature sensors placed inside their homes\n* Some participants may wear a lightweight wristband that tracks sleep and heart rate\n* In selected households, cooling improvements will be made, such as adding shade, applying reflective roof paint, or enhancing airflow\n\nPurpose:\n\nThis study seeks to identify affordable and effective strategies to help families stay safe during extreme heat, and to use these insights to support other vulnerable communities facing similar challenges.",[28,29],"Heat Illness","Quality of Life",[31,32,33,34,35,36,37,38],"heat illness","behaviour modification","personal cooling","Structural modification","heat adaptation","prevention","rural","Quality of life","RECRUITING","2026-06-23",{"date":42,"type":43},"2026-06-25","ACTUAL",{"date":45,"type":43},"2026-01-01",{"date":47,"type":22},"2028-02",{"name":49,"class":50},"Aga Khan University","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":18,"sex":19,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100641803","hbm-based-education-for-retinopathy-of-prematurity-screening-in-parents-of-premature-infants-100641803","NCT07661654","HBM-Based Education for Retinopathy of Prematurity Screening in Parents of Premature Infants","Impact of Health Belief Model-Based Education on Retinopathy of Prematurity Screening Knowledge and Practices in Parents of Premature Infants: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Mother or father of a premature infant attending Retinopathy of Prematurity (ROP) clinic\n* Parent aged 18 years or older\n* Parent of a premature infant who was admitted to the Neonatal Intensive Care Unit (NICU)\n* Able to understand English or Urdu\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Parents with disability or cognitive impairment affecting participation\n* Uncooperative participants\n* Parents unwilling or unable to provide informed consent","18 Years",{"count":61,"type":22},99,[25],"The goal of this clinical trial is to learn whether Health Belief Model (HBM)-based educational interventions can improve knowledge and practices related to Retinopathy of Prematurity (ROP) screening among parents of premature infants attending ROP clinics in Karachi, Pakistan. The main questions it aims to answer are:\n\n* Do HBM-based educational interventions improve parents' knowledge about Retinopathy of Prematurity screening?\n* Do HBM-based educational interventions improve parents' screening-related practices and follow-up for Retinopathy of Prematurity?\n\nResearchers will compare different educational approaches, including video-based education, audio-based education, and standard educational material, to see which method is more effective in improving parental understanding and practices regarding ROP screening.\n\nParticipants will:\n\n* Complete a questionnaire assessing their knowledge and practices related to Retinopathy of Prematurity screening at baseline\n* Receive one of the following educational approaches: video message plus counselling and pamphlet, audio message plus counselling and pamphlet, or counselling and pamphlet only\n* Attend a follow-up visit approximately 2 weeks after the initial visit\n* Complete a follow-up questionnaire to assess changes in knowledge and practices related to Retinopathy of Prematurity screening",[65],"Retinopathy of Prematurity (ROP)","NOT_YET_RECRUITING","2026-06-16",{"date":69,"type":43},"2026-06-22",{"date":71,"type":22},"2026-07",{"date":73,"type":22},"2027-04",{"name":49,"class":50},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":18,"sex":19,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100627693","effectiveness-of-small-quantity-vs-medium-quantity-lipid-based-nutrient-supplements-for-prevention-of-undernutrition-in-children-6-12-months-100627693","NCT07451951","Effectiveness of Small-Quantity vs Medium-Quantity Lipid-Based Nutrient Supplements for Prevention of Undernutrition in Children 6-12 Months","Effectiveness of Small-Quantity vs Medium-Quantity Lipid-Based Nutrient Supplements for Prevention of Undernutrition in Children Aged 6-12 Months: An Individually Randomized, Parallel-Group, Non-Inferiority Trial","Inclusion Criteria:\n\n* Children aged 6 months (26 weeks) to 7 months and 15 days (33 weeks) with weight-for-length z-score (WLZ) ≥ -2 standard deviation (SD) and mid-upper arm circumference (MUAC) ≥125 mm, born to mothers who are beneficiaries of the Benazir Income Support Programme and registered with the Benazir Nashonuma Programme (BNP) at any point during their pregnancy.\n* Permanent residents of the selected districts, with no plan to relocate or migrate within the next 6 months.\n* Written informed consent provided by the child's caregivers.\n\nExclusion Criteria:\n\n* Children with moderate acute malnutrition (MAM), defined as WLZ ≥ -3 to \\\u003C -2 SD, or MUAC ≥115 mm to \\\u003C125 mm.\n* Children with severe acute malnutrition (SAM), defined as WLZ \\\u003C -3 SD or MUAC \\\u003C115 mm or presence of bilateral pitting edema, who require therapeutic feeding.\n* Children with known congenital anomalies, chronic illness, or conditions affecting growth or feeding (for example, cerebral palsy or congenital heart disease).\n* Children already enrolled in any nutritional supplementation other than BNP or another clinical trial.\n* Children whose families will be unwilling to provide informed consent, or likely to be unavailable for follow-up.","26 Weeks","33 Weeks",{"count":85,"type":22},980,[25],"Nutrition is essential for a child's growth, brain development, and protection from disease. While breastmilk provides the best nutrition for young infants, children older than six months may not get all the nutrients they need from breastmilk and regular foods alone. For this reason, some children receive special nutrient supplements to support healthy growth.\n\nLipid-based nutrient supplements (LNS) are one type of supplement that provides important vitamins and minerals. These supplements are used in many countries to help prevent undernutrition in young children. In Pakistan, the government social safety net program currently provides medium-quantity LNS to children starting at six months of age. However, it is not known whether a smaller-quantity LNS could provide similar benefits for children in this age group from under-resourced communities that have limited access to nutritious foods.\n\nThe goal of this trial is to learn whether small-quantity lipid-based nutrient supplements (SQ-LNS) work as well as medium-quantity lipid-based nutrient supplements (MQ-LNS) in preventing undernutrition in children aged six to twelve months.\n\nThe main questions this study aims to answer are:\n\n* Does SQ-LNS work as well as MQ-LNS in supporting healthy growth, including reducing stunting, wasting, and underweight?\n* Does SQ-LNS work as well as MQ-LNS in reducing anemia?\n\nResearchers will compare SQ-LNS and MQ-LNS to see if SQ-LNS is as good as MQ-LNS in preventing undernutrition.\n\nParticipants will:\n\n* Receive either SQ-LNS or MQ-LNS once daily for 6 months\n* Have their length, weight and mid-upper arm circumference (MUAC) measured monthly\n* Have their blood tested for anemia at the start and end of supplementation",[89],"Undernutrition",[91,92,93,94,95,96,97],"Stunting","Wasting","Anemia","Underweight","Small-quantity lipid-based nutrient supplement","Child nutrition","Medium-quantity lipid-based nutrient supplement","2026-05-29",{"date":100,"type":43},"2026-06-02",{"date":102,"type":43},"2026-02-26",{"date":104,"type":22},"2027-03-31",{"name":49,"class":50},2,{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":19,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":127,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":51},"100610251","goat-milk-derived-formula-vs-undiluted-goat-milk-in-infants-unable-to-exclusively-breastfeed-growth-and-biomarker-analysis-100610251","NCT07225153","Goat Milk-Derived Formula vs. Undiluted Goat Milk in Infants Unable to Exclusively Breastfeed: Growth and Biomarker Analysis","Goat Milk-Derived Formula Alternatives vs. Undiluted Goat Milk in Babies Unable to Exclusively Breastfeed: Analysis of Growth Metrics and Biological Markers","GMDFA","Inclusion Criteria:\n\n* • Infants aged = 08 -10 weeks with WAZ better than -1.8. (NIPS \\& ICF, 2019) Age Sex WAZ Weight in Kilograms 2 Month Boys WAZ\\>-1.8 4-5 kg 2 Month Girls WAZ\\>-1.8 4-5 kg Table 3: WAZ scores\n\n  * Living in Matiari District.\n  * Who has access to goat milk in their households.\n  * The Breastfeeding group: Women who exclusively breastfeeding and not giving and sort of formula or animal derived milk.\n  * Intervention Group: Women who do not breastfeed at all or give goat milk to their infants (2-3 feeds per day).\n  * No birth deformities\n\nExclusion Criteria:\n\n* • Infant birth weight \\\u003C WAZ -1.8 i.e. weight-for-age based on established growth standards, such as the World Health Organization (WHO).\n\n  * Birth deformities or disorders, such as genetic disorders, aerodigestive problems, or congenital anomalies.\n  * Plan to migrate during the next six months.\n  * We will exclude the women who exclusive breast feed and continue breast feeding for first 4 months.\n  * If the child is enrolled or included in any other interventional trial.\n  * Who does not have access to goat milk in their households.\n  * Are medically disqualified: Any potential participant who is deemed medically unfit for enrollment, due to the presence of severe or unstable health conditions that could compromise safety or interfere with the study outcomes, will be excluded from participation","8 Weeks","10 Weeks",{"count":118,"type":22},15,[25],"The goal of this clinical trial is to learn if Goat Milk-Derived Formula Alternatives (GMDFA) are safe and effective for infants who are unable to be exclusively breastfed. It will also study growth patterns, biological markers, and gut microbiome differences among infants receiving GMDFA, undiluted goat milk, or breast milk.\n\nThe main questions it aims to answer are:\n\n1. Do infants receiving GMDFA show similar growth patterns to those who are breastfed?\n2. Are biological markers of gut health and nutrition (such as calprotectin, lipocalin-2, CRP, and claudin) comparable between the groups?\n3. How do feeding types (GMDFA, goat milk, or breast milk) influence the infant gut microbiome composition, metabolic pathways, and lipid profiles?\n4. Is GMDFA a safe and nutritionally adequate feeding option for infants unable to be exclusively breastfed?\n\nWe will compare GMDFA, undiluted goat milk, and breast milk (reference group) to evaluate infant growth, gut health, and metabolic outcomes.\n\nParticipants will:\n\nBe randomly assigned to one of three feeding groups: GMDFA, undiluted goat milk, or breastfed\n\nAttend regular follow-up visits for growth measurements and sample collection (blood, stool, and breast milk where applicable)\n\nHave feeding practices monitored and recorded through caregiver interviews and feeding logs\n\nAdditional Analyses:\n\nMicrobiome analysis: to identify gut bacterial diversity and composition across feeding groups Metagenomic analysis: to explore functional genes and metabolic pathways related to nutrition and gut health Lipidomic analysis: to assess differences in lipid and fatty acid profiles in breast milk, goat milk, and infant samples",[122,123,124,125,126],"Malnutrition (Calorie)","Infant Nutrition Disorder","Growth Flatering","Gut Microbiome","Lipidomics",[128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,126,146,147],"Infant nutrition","goat milk","Infant feeding practices","Breastfeeding","Breastfeeding Alternatives","Alternate feeding practices","Growth outcomes","Infant growth metrics","Gut microbiome","Gut inflammation biomarkers","Calprotectin","Lipocalin-2","Claudin-2","C-reactive protein (CRP)","Randomized controlled trial","Rural Pakistan","Infant health","Malnutrition prevention","Breast milk","Metagenomics","2026-03-25",{"date":150,"type":43},"2026-03-30",{"date":152,"type":43},"2025-08-30",{"date":154,"type":22},"2026-03-18",{"name":49,"class":50},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":19,"minAge":163,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100629524","image-guided-genicular-nerve-radiofrequency-ablation-for-chronic-knee-osteoarthritis-100629524","NCT07475793","Image Guided Genicular Nerve Radiofrequency Ablation for Chronic Knee Osteoarthritis","Efficacy of Ultrasound vs Fluoroscopy Guided Genicular Nerve Radiofrequency Ablation for Chronic Knee Osteoarthritis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Both gender patients of age more than 50 years.\n* Radiographic diagnosis of knee OA with KL level 3 and 4.\n* Chronic knee pain for more than 6 months\n* Patients with more than 50% reduction in pain intensity after diagnostic genicular nerve block\n\nExclusion Criteria:\n\n* Lack of consent\n* surgery of knee\n* Patient with BMI more than 40kg\u002Fm2\n* Intra-articular steroid injection or hyaluronic acid in last 3 months\n* Localized infection at procedure site or knee.\n* Patient unable to communicate properly (Severe psychiatric illness, severe dementia and cognitive impairment).\n* Patients have moderate to severe low back pain (NRS ≥5)","50 Years",{"count":165,"type":22},52,[25],"The goal of this prospective randomized control trial is to provide continued pain relief, classically long-lasting 3 to12 months, and enhanced function in patients following: both gender; male and female, age group; \\>50yr, healthy volunteers along with Radiographic diagnosis of knee OA with KL grade 3 and 4 in addition of Chronic knee pain ≥ 6 months and patients with ≥50% decrease in pain strength after diagnostic genicular nerve block. The main question it aims to answer is:\n\nIs ultrasound-guided genicular nerve RFA more efficient in lowering pain intensity at six months contrasted with fluoroscopic guided method in patients with chronic knee osteoarthritis? Researchers will compare Group A (Fluoroscopic) to Group B (Ultrasound) to see comparison in efficiency of ultrasound guided against fluoroscopic guided genicular nerves block for decrease in pain intensity and functional improvement.",[169],"Chronic Knee Osteoarthritis","2026-03-24",{"date":172,"type":43},"2026-03-27",{"date":174,"type":22},"2026-05-01",{"date":176,"type":22},"2027-05-31",{"name":49,"class":50},{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":18,"sex":185,"minAge":59,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":196,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":51},"100630591","indigenous-nutritional-supplements-for-pregnancy-to-improve-resilience-in-environmental-heat-100630591","NCT07489664","Indigenous Nutritional Supplements for Pregnancy to Improve Resilience in Environmental Heat","INSPIRE","Inclusion Criteria:\n\n1. Women aged 18-45 years belonging to a low to middle socioeconomic status, residing in Mithi, Districts in Sindh.\n2. Planning to conceive within the study time frame and expect to become pregnant within four months of starting nutritional intervention.\n3. Women who confirm their pregnancy during the first trimester i.e., before 8 weeks of gestational age.\n\nExclusion Criteria:\n\n1. Women using long-lasting contraceptives such as IUDs, implants, and injectable methods like Depo-Provera.\n2. Women with a history of multiple miscarriage or stillbirths.\n3. Women with known chronic diseases, such as cardiovascular disorders, hepatic disorders, renal disorders, and infectious diseases.\n4. Women suffering from severe malnutrition (WHO: Underweight i.e., having BMI \\\u003C 16 Kg\u002Fm2 or obese having BMI ≥ 30 Kg\u002Fm2).\n5. Women having severe anemia (WHO: Severe anemia i.e., Hb \\\u003C 7g\u002FdL).\n6. Women currently enrolled in BISP supplementation programs or taking any supplements other than iron and folic acid (IFA) will be excluded from the study.\n7. Those who do not become pregnant within three months of supplementation during pre-conception.","FEMALE","45 Years",{"count":188,"type":22},292,[25],"The purpose of this study is to learn whether a simple, traditional, and balanced meal made from local foods, eaten once a day during pregnancy, can help women in rural Pakistan stay healthier in hot weather and give birth to healthier babies. Climate change has made heat a serious challenge for pregnant women, especially in areas with limited resources. This study will explore whether an indigenous meal that is culturally acceptable and easy to prepare can improve resilience to heat stress and support better outcomes for both mothers and newborns.\n\nThe study will focus on two main questions:\n\n* Can this daily balanced meal reduce the harmful effects of heat stress during pregnancy?\n* Does it improve newborn health, especially birth weight?\n\nResearchers will compare women who eat the balanced local meal every day with women who continue their usual meals. They will check changes in women's health, levels of key vitamins and nutrients, and their babies' birth outcomes.\n\nDuring the study, participants will:\n\n* Either eat the balanced local meal daily or continue their usual meals.\n* Share information on their health, diet, and heat exposure.\n* Provide small samples, such as blood and stool, to study nutrient levels and gut health.\n* Have their newborns' health and growth measured at birth.",[192,193,194,195],"Heat Stress","Pregnancy","Women of Reproductive Age","Nutrition Status",[197,198,199,200],"Local Food-Based Diet to Improve Birth Outcomes and Heat Resilience in Pregnant Women","maternal depression","placental transcriptomics","microbiome","2026-03-19",{"date":170,"type":43},{"date":204,"type":22},"2026-03",{"date":206,"type":22},"2028-12",{"name":49,"class":50},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":19,"minAge":59,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":220,"conditions":221,"keywords":224,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100627519","phase-4-comparing-acotiamide-and-itopride-for-the-management-of-indigestion-100627519","NCT07449689","Comparing Acotiamide and Itopride for the Management of Indigestion","A Double-Blind Superiority Randomized Controlled Trial Comparing Acotiamide vs Itopride for Functional Dyspepsia Management","Inclusion Criteria\n\n* Patients experiencing bothersome post-prandial fullness or bothersome early satiation at least three days a week.\n* Symptom onset must have occurred six months prior to diagnosis, and symptoms must have been present for at least the past three months.\n* No evidence of organic, systemic, or metabolic disease based on clinical investigations and endoscopy.\n* Patients with co-existing symptoms of Epigastric Pain Syndrome (EPS) are included only if the symptoms causing the most distress are meal-related.\n* Individuals who have already tested negative for H. pylori (separate tests will not be conducted for the study).\n\nExclusion Criteria\n\n* Patients with an identifiable organic disease that can explain their symptoms, such as peptic ulcer, GERD, or chronic pancreatitis.\n* Patients with a history of gastrointestinal surgery.\n* History of malignancy in the past five years.\n* Patients having major psychiatric or depressive disorders.\n* Patients with a history of drug or alcohol abuse.\n* Patients with advanced chronic kidney disease.\n* Patients with uncontrolled diabetes (HbA1c \\>8).\n* Patients with uncontrolled hypertension.\n* Patients diagnosed with Irritable Bowel Syndrome.\n* Pregnant or lactating women.\n* Patients who have used antibiotics, opioids, or any other medication that -affects gastrointestinal function in the past 4 weeks.\n* H. pylori positive patients.\n* Patients who cannot fill out scales or record their symptoms.","70 Years",{"count":217,"type":22},368,[219],"PHASE4","This study is a randomized, double-blinded trial that will compare the effectiveness of two medications, acotiamide and itopride, in treating Functional Dyspepsia. Functional Dyspepsia causes uncomfortable symptoms arising from the gastro-duodenal region, such as fullness after meals, early satiation, stomach pain, and burning.\n\nThe primary aim of this trial is to determine whether acotiamide is superior to itopride-specifically by a margin of 15%-at improving these meal-related digestive symptoms.\n\nParticipants will be involved in the study for a total of 5 weeks. The study begins with a 7-day baseline period where participants will track their symptoms daily.\n\nFollowing the baseline period, participants will be randomly assigned to receive either 100mg of acotiamide three times a day or 50mg of itopride three times a day.\n\nThe treatment phase will last for 4 weeks, during which participants will take the medication before meals on an empty stomach.\n\nParticipants will continue to track their symptoms daily and will complete questionnaires about their overall treatment effect and quality of life at follow-up visits.",[222,223],"Functioanl Dyspepsia","Post Prandial Distress Syndrome",[225,226,227,228,229],"Functional Dyspepsia","Acotiamide","Itopride","Post-Prandial Distress Syndrome","Gastroprokinetic","2026-03-05",{"date":232,"type":43},"2026-03-06",{"date":234,"type":22},"2026-04",{"date":236,"type":22},"2027-05",{"name":49,"class":50},{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":185,"minAge":59,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":4},"100608140","ultrasound-guided-pecs-block-and-ketamine-infusion-for-preventing-chronic-pain-in-patients-undergoing-breast-cancer-surgery-100608140","NCT07197684","Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surgery","Effect of Ultrasound Guided Pecs Block With Intravenous Ketamine and Ketamine Infusion Alone For Prevention of Chronic Post-Surgical Pain in Patients Undergoing Breast Cancer Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult female patients with breast cancer aged between 18-75 years\n* ASA (American Society of Anesthesia) physical status I, II, and III\n* Patients scheduled for elective breast cancer surgery (Mastectomy with or without axillary clearance)\n\nExclusion Criteria:\n\n* Refusal to participate or withdrawal of informed consent\n* Surgical procedures involving breast reconstruction with flaps or implants\n* Patient scheduled for bilateral mastectomy\n* Reoperation on the same side due to cancer recurrence\n* Known allergy or contraindication to study drugs\n* History of severe psychiatric illness (e.g., major depression, bipolar disorder, schizophrenia)\n* Chronic opioid use, substance abuse, or opioid addiction\n* Pre-existing chronic pain or neuropathic pain disorders\n* Coagulopathy, anticoagulation therapy, or localized infection at the site of block\n* Uncontrolled hypertension and ischemic heart disease","75 Years",{"count":247,"type":22},120,[25],"The goal of this clinical trial is to is to compare the effectiveness of ultrasound-guided Pecs block with intravenous ketamine versus intravenous ketamine infusion alone in preventing Chronic Post-Surgical Pain (CPSP) in patients undergoing breast cancer surgery. The main question it aims to answer is,\n\nHow effective is the ketamine and ketamine with pecs block in reducing the frequency of Chronic Post-Surgical Pain after breast cancer surgery",[251,252,253],"Breast Cancer","Pain, Chronic","Post Surgical Pain","2026-02-17",{"date":256,"type":43},"2026-02-19",{"date":258,"type":22},"2026-03-16",{"date":260,"type":22},"2027-05-01",{"name":49,"class":50},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":185,"minAge":269,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":51},"100601904","phase-4-impact-of-eras-protocol-on-length-of-hospital-stay-after-laparoscopic-surgeries-100601904","NCT07116564","Impact of ERAS Protocol on Length of Hospital Stay After Laparoscopic Surgeries","Impact of Multimodal Analgesia and ERAS Protocol on Length of Hospital Stay After Laparoscopic Gynecological Surgeries: A Randomized Control Trial","Inclusion Criteria:\n\n* ASA physical status I, II, and III\n* Patients scheduled for elective laparoscopic gynecological surgeries\n\nExclusion Criteria:\n\n* Refusal to participate\n* History of allergy or contraindication to study drugs\n* Patients in which procedure converted to open surgery\n* Diagnostic laparoscopic procedures\n* Patients with a history of severe anxiety or depression","20 Years","60 Years",{"count":272,"type":22},98,[219],"The goal of this clinical trial is to determine the length of hospital stay in patients using multimodal analgesia with or without ERAS protocol scheduled for elective laparoscopic gynecological surgeries",[276],"ERAS","2026-02-12",{"date":254,"type":43},{"date":280,"type":43},"2025-08-20",{"date":282,"type":22},"2026-11-01",{"name":49,"class":50},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":18,"sex":185,"minAge":59,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":299,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":51},"100484615","efficacy-of-mobile-health-application-in-promotion-of-exclusive-breast-feeding-and-young-child-feeding-practices-in-pakistan-100484615","NCT05590351","Efficacy of Mobile Health Application in Promotion of Exclusive Breast Feeding and Young Child Feeding Practices in Pakistan","Efficacy of Mobile Health Application in Promotion of Exclusive Breast Feeding and Young Child Feeding Practices in Pakistan: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Pregnant women in the third trimester at 36 +\u002F- 1 week of gestation.\n2. Planned to stay in their respective areas for at least 1 year after delivery\n3. Planned to get the infant immunized from the respective FHC of the hospitals.\n4. Have access to smart phones with internet connection.\n5. Registered and planning to deliver to any of the Secondary Care Hospitals\n6. Can read and write in local language (English and\u002For Urdu).\n7. Consent to participate and remain in the study until 1 year of child age\n\nExclusion Criteria:\n\n1. High-risk including maternal neurological\u002Fheart\u002F autoimmune\u002Frenal disease, preeclampsia, placenta previa, multiple gestations (twins\u002Ftriplets), fetal structural\u002Fgenetic anomalies, fetal growth restrictions, and birth trauma\u002Frequiring NICU admission.\n2. Women who plan to move to different location after delivery","48 Years",{"count":293,"type":22},300,[25],"Early life nutrition is the key modifiable determinant of child growth, development, survival and diseases of adult onset. Pakistan ranks highest for neonatal mortality rate (44.2\u002F1000 live births (LBs)) globally. One third of under-five deaths (74.9\u002F1000 LBs) are attributable to high prevalence of stunting (38%), underweight (23%) and wasting (7%), greatly related to feeding practices. Given the low prevalence of exclusively breast fed (EBF) (48%) and use of minimum acceptable diet (13%), mitigation of early life nutritional risk through promotion of EBF and Young Child Feeding Practices (YCFP) provides a critical window of opportunity for intervention. Secondary Care Hospitals (SCH) of the Aga Khan Health Services Pakistan provide essential maternal and child health services for low-middle income population. Babies born at these SCHs are followed up for vaccination, growth-monitoring and other services at the closely affiliated Family Health Centers (FHCs) run by Lady Health Visitors (LHVs). We aim to examine the effectiveness of a locally designed m-Health application for empowering mothers for child nutritional care as a potentially sustainable approach. The first six months of formative research would identify perceptions, barriers and facilitators for EBF and YCFP using self-determination behavioral theory, among multi-parous pregnant mothers enrolled at three SCHs of Karachi. A randomization trial would be conducted during next 18 months among near-term pregnant women who have access to smart-phones. A culturally appropriate mhealth application called first diet would be developed to provide personalized push messages delivered weekly by the LHVs. Non-intervention group will receive face-face nutritional counselling by the research staff at FHC following routine vaccination and growth-monitoring schedule. Mothers would followed-up from one month prior to expected delivery to child's first birthday. We expect 20% improvement in rates of EBF and YCFP with m-Health intervention. If proven effective, m-health would be incorporated in routine child care provision by LHVs.",[297,298],"Malnutrition, Infant","Malnutrition, Child",[300,301,302],"infant & young child feeding practices","stunting","wasting","2026-02-10",{"date":277,"type":43},{"date":306,"type":43},"2026-02-02",{"date":308,"type":22},"2027-12",{"name":49,"class":50},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":318,"conditions":319,"keywords":320,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":326,"leadSponsor":327,"locationsCount":51},"100592293","structural-heat-adaptation-and-education-in-urban-setting-100592293","NCT06991543","Structural Heat Adaptation and Education in Urban Setting","Structural Heat Adaptation and Education in Urban Setting (SHAPES Trial)",{"count":21,"type":22},[25],"This study aims to understand whether simple, low-cost interventions, such as improved home cooling, practical advice, and minor home modifications, can help protect people's health and improve quality of life during periods of extreme heat in densely populated, low-income neighborhoods of Karachi, Pakistan.\n\nKey Questions the Study Seeks to Answer:\n\n1. Can these interventions reduce heat-related health problems such as dizziness, headaches, and heatstroke and improve the quality of life?\n2. Can they lower indoor temperatures and improve sleep quality, comfort, and daily functioning?\n\nTo answer these questions, researchers will compare communities where families receive heat-related support and information with similar communities that do not, to assess any differences in health and well-being.\n\nWhat Participants Can Expect:\n\n* Answer questions about their health, living conditions, and how they cope with heat\n* Have small temperature sensors placed inside their homes\n* Some participants may wear a lightweight wristband that tracks sleep and heart rate\n* In selected households, cooling improvements will be made, such as adding shade, applying reflective roof paint, or enhancing airflow\n\nPurpose:\n\nThis study seeks to identify affordable and effective strategies to help families stay safe during extreme heat, and to use these insights to support other vulnerable communities facing similar challenges.",[28,29],[31,32,33,34,35,36,321],"quality of life","2026-01-25",{"date":324,"type":43},"2026-01-27",{"date":45,"type":43},{"date":308,"type":22},{"name":49,"class":50},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":343,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":4},"100620318","self-efficacy-enhancement-using-a-multicomponent-support-group-for-caregivers-of-children-with-dmdsma-100620318","NCT07356063","Self-Efficacy Enhancement Using a Multicomponent Support Group for Caregivers of Children With DMD\u002FSMA","Effect of a Multicomponent Support Group on Self-Efficacy of Primary Caregivers of Children With Spinal Muscular Atrophy or Duchenne Muscular Dystrophy Enrolled in Treat-NMD Registry of Pakistan","SEE-NMD","Inclusion Criteria:\n\n* Primary caregiver of a child diagnosed with SMA or DMD.\n* Enrolled in the Treat-NMD registry- Pakistan.\n* Access to a smart phone with internet connectivity.\n\nExclusion Criteria:\n\n* Caregivers who are currently participating in another support group intervention.\n* Caregivers who are unable to understand the language of communication (Urdu)",{"count":337,"type":22},30,[25],"The goal of this clinical trial is to learn if providing a multicomponent intervention improves the confidence of caregivers of children with DMD or SMA. The main question it aims to answer is:\n\nDoes this intervention increase their self-efficacy scores over 8 weeks time?\n\nResearchers will compare scores at baseline (pre intervention) and after 8 weeks (post intervention)",[341,342],"Duchenne Muscular Dystrophy (DMD)","Spinal Muscular Atrophy (SMA)",[344,345,346,347,348,349],"DMD","SMA","Self-Efficacy","Caregivers","Treat-NMD","Muscular Dystrophy","2026-01-21",{"date":352,"type":43},"2026-01-22",{"date":354,"type":22},"2026-02-23",{"date":356,"type":22},"2026-05-23",{"name":49,"class":50},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":19,"minAge":59,"maxAge":365,"enrollmentInfo":366,"targetDuration":4,"studyType":368,"phases":4,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":4},"100620417","effectiveness-of-pain-management-interventions-in-patients-with-abdominal-and-pelvic-cancer-100620417","NCT07357350","Effectiveness of Pain Management Interventions in Patients With Abdominal and Pelvic Cancer","Effectiveness of Pain Management Interventions in Patients With Abdominal and Pelvic Cancer in a Tertiary Care Hospital: A Prospective Observational Study","Inclusion Criteria:\n\n* Patients with chronic pain due to abdominal and pelvic cancer\n* Both Male and Female\n* Ages18-65 years\n* Patients who with recurrence or metastasis\n\nExclusion Criteria:\n\n* Patients who refuse to give consent\n* Patients who were lost to follow up after initial visit or assessment\n* History of severe depression or psychiatric illness\n* History of surgical procedure due to cancer\n* Patients with DNR code","65 Years",{"count":367,"type":22},100,"OBSERVATIONAL","The goal of this prospective observational study is to observe the effectiveness of pain management interventions in patients with abdominal and pelvic cancer pain.\n\nThe main question\\[s\\] it aims to answer are:\n\n* The effectiveness of pain management interventions.\n* The frequency of pain intervention procedures and side effects and complications of pain management interventions",[371],"Abdominal Cancer","2026-01-15",{"date":352,"type":43},{"date":375,"type":22},"2026-01-16",{"date":377,"type":22},"2026-12-31",{"name":49,"class":50},{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":18,"sex":19,"minAge":269,"maxAge":365,"enrollmentInfo":387,"targetDuration":4,"studyType":23,"phases":389,"briefSummary":390,"conditions":391,"keywords":396,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":51},"100591501","cardiovascular-disease-prevention-strategies-for-high-risk-urban-sedentary-employees-in-karachi-pakistan-100591501","NCT06981247","Cardiovascular Disease Prevention Strategies for High-risk Urban Sedentary Employees in Karachi, Pakistan","m-Lifestyle Intervention for Employees (m-LIfE): Protocol for a Pilot Cluster Randomized Controlled Trial on Cardiovascular Disease Prevention Strategies","m-LIfE","Inclusion Criteria:\n\n• At least 6 months of job experience in any bank\n\nExclusion Criteria:\n\n* Diagnosed case of myocardial infarction, stroke, coronary heart disease, cerebrovascular disease, or peripheral arterial diseases\n* Pregnant women\n* Individuals with acute illnesses that limit physical activity",{"count":388,"type":22},84,[25],"Heart diseases and other non-communicable diseases are serious health issues in countries like Pakistan. Many people who work in offices, like bank employees, sit for more than 8 hours a day. This is called a sedentary lifestyle, and it increases the risk of heart diseases.\n\nThis research project aims to find out if a newly developed context specific mobile phone application can help these sedentary employees to improve their lifestyle. The app, called m-LIfE (mHealth-based Lifestyle Intervention for Employees), will be designed to help employees to move more during the day and eat healthier food like fruits and vegetables.\n\nThe study will involve bank employees in urban Karachi, Pakistan. They will be divided into two arms:\n\nIntervention arm: Participants in this arm will use the m-LIfE app for 12 weeks. They will get reminders and tips to take breaks, exercise, and eat healthy.\n\nRoutine care arm: Participants in this arm will receive printed basic educational material about prevention of risk factors of heart diseases and improving lifestyle.\n\nAfter the 12 weeks of intervention, there will be a follow-up period at 4th week to check if participants are maintaining healthy habits.\n\nThis study could help find simple and affordable ways to improve the health of office workers and reduce pressure on the healthcare system.",[392,393,394,395],"Physical Activity","Life Style","Dietary Habits","Cardiovascular Diseases",[397,398,399,400,401,402,403,404,405,406],"Primary care","Cardiology","Preventive medicine","risk perception","cardiovascular health","CVD","Sedentary lifestyle","mHealth","Digital health","Feasibility","2025-12-14",{"date":409,"type":43},"2025-12-17",{"date":411,"type":22},"2026-01",{"date":413,"type":22},"2026-08",{"name":49,"class":50},{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":18,"sex":185,"minAge":59,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":368,"phases":4,"briefSummary":424,"conditions":425,"keywords":435,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":451},"100589696","biological-impacts-of-rising-temperatures-on-maternal-fetal-and-newborn-health-a-cohort-study-birth-cohort-100589696","NCT06957769","Biological Impacts of Rising Temperatures on Maternal, Fetal, and Newborn Health: A Cohort Study (BIRTH Cohort)","BIRTH","Inclusion Criteria:\n\n* Single or multiple live pregnancy confirmed through ultrasound\n* Gestational age less than or equal to 13 weeks and 6 days at enrollment\n* At least 18 years of age\n* Permanent resident of the study district and plans to deliver within the district\n* Willing and able to attend study clinic visits and comply with study procedures throughout pregnancy\n\nExclusion Criteria:\n\n• Plan to relocate outside the district for more than 3 months during the study period",{"count":423,"type":22},6000,"The goal of this study is to learn how being exposed to high environmental temperatures during pregnancy affects the health of pregnant women and their babies. The study also aims to understand how the body responds to heat stress during pregnancy and how this might lead to pregnancy complications and birth problems like early birth or low birth weight.\n\nThe main questions that the study aims to answer are:\n\n1. What are the acute and chronic effects of environmental heat exposure on pregnancy and birth outcomes across different trimesters?\n2. Through which biological pathways does heat stress impact maternal, fetal, and infant health across varying gestational ages?\n3. How do socio-demographic factors, maternal characteristics, and nutritional status of women modify the relationship between environmental heat exposure and adverse pregnancy outcomes?\n\nThe study will take place in rural parts of Sindh, Pakistan. These areas often experience extreme heat and have limited access to electricity or cooling systems like fans or air conditioners.\n\nThis study will include pregnant women who are in their first trimester (under 14 weeks of pregnancy). Before starting any study activities, researchers will explain the study to each woman in a language she understands and ask for her written permission to take part (informed consent).\n\nAt the beginning of the study, participants will visit a study clinic. During this visit, researchers will check their height and weight, perform an ultrasound, and collect a small amount of blood for testing. Participants will also be asked to wear a small device that measures the air temperature and humidity in their surroundings.\n\nThe researchers will follow each participant during her pregnancy, with visits during the second and third trimesters at the study clinic. At each visit, researchers will check how much heat the participant has been exposed to using the data from the device and from her own answers to a simple questionnaire. The questionnaire will have questions about their heat exposure at work, home, type of clothing, and how they deal with hot weather. Serial ultrasound, blood and urine tests will be conducted so researchers can study signs of stress, hydration, and other changes in the body. A smaller group of participants will also wear a device to measure their body skin temperature, heart rate, physical activity and sleep during pregnancy.\n\nWhen the baby is born, researchers will collect information about the birth, including the baby's weight and length, the time of delivery, and whether there were any complications during birth. After delivery, both the mother and baby will be followed for up to 12 months. During this time, the research team will check the health of both the mother and baby and see how heat exposure during pregnancy may affect the baby's growth over time. At delivery, placental weight and volume will be collected for a smaller group of women. Breastmilk sampling will also be done for this group of women to understand the effect of high temperatures on breastmilk quality.\n\nThis study does not involve any treatment or medicine. Instead, researchers will observe the participants to learn how real-life heat exposure affects them during pregnancy. The findings from this study may help public health officials and governments find better ways to protect pregnant women and babies from the harmful effects of climate change and extreme heat, especially in places with limited resources.",[426,427,428,429,430,431,432,433,434],"Low Birth Weight Baby","Small for Gestational Age (SGA)","Preterm Birth","Pregnancy Complications","Birth Outcome, Adverse","Heat Strain","Infant Morbidity","Infant Mortality","Neonatal Mortality",[436,437,438,439,440,441,442],"heat stress","high ambient temperature","climate change","birth outcomes","pregnancy","cohort study","Pakistan","2025-11-26",{"date":445,"type":43},"2025-12-03",{"date":447,"type":43},"2025-05-07",{"date":449,"type":22},"2028-06-30",{"name":49,"class":50},3,{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":18,"sex":185,"minAge":460,"maxAge":461,"enrollmentInfo":462,"targetDuration":4,"studyType":23,"phases":464,"briefSummary":466,"conditions":467,"keywords":474,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":51},"100595194","phase-3-the-mom-care-trial--evaluating-antenatal-and-postnatal-mmsplus-for-improved-infant-birth-and-growth-outcomes-100595194","NCT07029282","The MOM-CARE Trial : Evaluating Antenatal and Postnatal MMSPlus for Improved Infant Birth and Growth Outcomes","A Phase III Double-Blind, Adaptive Randomized Trial of Antenatal MMSPlus Versus UNIMAPP MMS and Postnatal MMSPlus Versus UNIMAPP MMS or IFA to Improve Infant Birth Outcomes and Growth at 6 Months","MOM-CARE","Antenatal Phase::\n\nInclusion Criteria:\n\n* Gestational age confirmed by ultrasound to be 8-14 weeks\n* Singleton and viable fetus on ultrasound\n* A resident of the catchment area for at least the last six months\n* Plans to stay within the catchment area during the pregnancy duration, during delivery and after birth of the baby.\n* Has provided voluntary written informed consent\n\nExclusion Criteria:\n\n* Women with known allergies or intolerance to any components of the MMS or MMS PLUS being studied\n* Women with pre-existing health conditions such as history of uncontrolled diabetes and hypertension or other chronic illnesses\n* Substance abuse, such as recreational drugs or smoking tobacco. Women chewing tobacco will not be excluded.\n\nPostnatal Phase::\n\nInclusion Criteria:\n\n* Birth weight available within 72 hours\n* Intention to breastfeed for 6 months\n* Resides in the study area for the duration of the trial\n* Has provided voluntary written informed consent\n\nExclusion Criteria:\n\n* Congenital anomalies, birth defects, or severe neonatal complications\n* Infants who are already receiving supplemental formula feeding or other nutritional supplements (except pre-lacteal feeding, vitamins, and medications)\n* Infants whose mothers have conditions that significantly affect breastfeeding, such as severe postpartum depression, insufficient milk supply, or maternal use of medications that contraindicate breastfeeding","15 Years","49 Years",{"count":463,"type":22},3000,[465],"PHASE3","This clinical trial aims to learn if MMS Plus improves infant health compared to standard MMS during pregnancy and the postnatal period in women living in peri-urban areas of Karachi, Pakistan. It will also evaluate how MMS Plus affects infant growth during the first 6 months of life.\n\nThe main questions it aims to answer are:\n\n1. Does MMS Plus during pregnancy reduce the risk of poor infant outcomes compared to standard MMS, as measured on a 5-point ordinal scale ranging from perinatal mortality to term birth with appropriate, small, or large-for-gestational-age infants?\n2. Does postnatal MMS Plus improve infant length velocity at 6 months of age among exclusively breastfed infants compared to standard MMS and iron\u002Ffolic acid (IFA) supplementation?\n\nResearchers will compare:\n\n1. MMS Plus versus standard MMS during pregnancy (antenatal phase)\n2. MMS Plus versus standard MMS versus IFA after birth (postnatal phase)\n\nParticipants will:\n\n1. Be randomly assigned to receive either MMS Plus or standard MMS during pregnancy\n2. Be re-randomized after delivery to receive either MMS Plus, standard MMS, or IFA supplements during the postnatal period\n3. Receive supplements under double-blind conditions\n4. Be followed through childbirth and until the infant is 6 months of age\n5. Attend regular clinic visits for health monitoring, infant assessments, and data collection.\n\nThis phase III adaptive randomized controlled trial will occur in three peri-urban catchment areas of Karachi, Pakistan.",[468,469,470,471,472,473],"Newborn Health","Multiple Micronutrient Deficiencies During Pregnancy","Nutrition During Pregnancy","Adaptive Trial","Postnatal Growth","Neurodevelopment Outcome",[475,476,477,478],"Antenatal Phase","Postnatal Phase","Micro Nutrient Supplementation","Infant Growth","2025-10-01",{"date":481,"type":43},"2025-10-07",{"date":483,"type":43},"2025-07-08",{"date":485,"type":22},"2027-12-31",{"name":49,"class":50},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":185,"minAge":59,"maxAge":461,"enrollmentInfo":495,"targetDuration":4,"studyType":23,"phases":497,"briefSummary":499,"conditions":500,"keywords":502,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":515,"leadSponsor":516,"locationsCount":51},"100608890","phase-2-maternal-probiotic-intervention-to-improve-gut-health-trial-ii-pakistan-100608890","NCT07207434","Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan","Ability of VE818 to Reduce Enteropathogen Colonization and Improve Environmental Enteropathy in Pregnant Women: a Proof of Concept and Phase II Randomized Placebo-controlled Trial in Bangladesh, Pakistan, Zambia and Burkina Faso","MPIGH-II","Inclusion criteria\n\n* Women aged 18 years or older in their first or early second trimester of pregnancy (13-17 weeks of gestational age \\[GA\\]), living in defined geographical areas of Bangladesh (Matlab), Pakistan, Zambia, and Burkina Faso, where it can be assumed that environmental enteropathy is prevalent\n* Presence of any 2 out of 11 selected bacterial pathogen targets (Aeromonas, Campylobacter coli, Campylobacter jejuni, Campylobacter Pan, Enteroaggregative Escherichia coli, Enteropathogenic Escherichia coli, Enterotoxigenic Escherichia coli, Plesiomonas, Shigella\\_EIEC, Salmonella and Klebsiella pneumoniae in fecal samples measured by TAC-qPCR.\n* Presence of any of the following WASH conditions -\n\n  1. use surface water, unimproved water, or limited water for drinking; OR\n  2. use surface water, unimproved water, or limited water for cooking; OR\n  3. use surface water, unimproved water, or limited water for washing utensils; OR\n  4. practice open defecation, use unimproved sanitation (toilet facility), or limited sanitation (toilet facility); OR\n  5. lack facility or have limited facility for handwashing\n\nExclusion criteria\n\nPotential participants will not be enrolled if they:\n\n* have MUAC ≥30 cm\n* are carrying more than one fetus (i.e., multiple pregnancy)\n* have diarrhea, defined as the passage of three or more loose stools per 24 hours, or have had diarrhea in the preceding 14 days\n* have fever or an active infection\n* have taken antibiotics or probiotics in the preceding 14 days\n* have taken steroids or non-steroidal anti-inflammatory drugs in the preceding 14 days\n* have severe anemia as determined using finger stick Hb \\\u003C 8 g\u002Fdl\n* have a history of chronic digestive disease\n* have any gastrointestinal contraindication to ingestion of a capsule (known or suspected gastrointestinal obstruction, stricture, fistula, gastroparesis, or any swallowing disorder)\n* have known immunocompromised status (known history of HIV infection, autoimmune disease, diabetes mellitus, etc.)\n* have known drug hypersensitivity\u002Fallergy\u002Fintolerance\n* have chronic disease or any other illness or condition which in the opinion of the investigator will complicate the assessment of safety or efficacy\n* are medically disqualified: Any potential participant who is deemed medically unfit for trial enrollment by a non-study healthcare provider, due to the presence of severe or unstable health conditions that could compromise safety or interfere with the study outcomes, will be excluded from participation\n* have a plan to observe fast any time during the intervention period\n* have a plan to leave the study area within the follow-up period\n* are participating in any other interventional trial\n* belong to a household from which another woman is already enrolled in the study\n* but may be enrolled if\u002Fwhen these disqualifiers have expired.",{"count":496,"type":22},144,[498],"PHASE2","Burden: Environmental Enteric Dysfunction (EED) is an enteropathic condition characterised by altered gut permeability, infiltration of immune cells, and changes in villous architecture and cell differentiation. EED is a major reason of malnourishment, poor neurological development, stunting, oral vaccine failure, and infection. It is believed that EED is responsible for 40% of all childhood stunting.\n\nRelevance: This trial aims to investigate the concept that a probiotic or live biotherapeutic product, capable of improving gut microbiota composition, can also displace enteropathogens and reduce biomarkers of intestinal inflammation, thereby promoting gut health. This will restore healthy microbial signalling to the host epithelium, ameliorate barrier function through secretion of mucus and antimicrobial factors, and improve nutrient availability.\n\nObjectives: The primary objective is to assess if administration of oral vancomycin followed by VE818 to pregnant women colonised with at least 2 out of 11 selected bacterial enteropathogens results in a significant change in the mean count of these organisms between the baseline and 2 weeks after completion of the intervention (Study Day 35d +2), compared to oral vancomycin followed by placebo.\n\nMethods: Pregnant women will be recruited from the community of Matiari in Pakistan. The study population will be women aged 18 years or older in the first trimester or early second trimester of pregnancy. Study procedures will be explained in detail, and written consent will be taken before enrollment. Those women who give consent to participation will undergo a screening process, which will check if any exclusion criteria are fulfilled. After consent and screening, they will be randomised into one of the three arms: intervention arm (oral vancomycin followed by VE818), placebo-control arm (oral vancomycin followed by placebo), or observation-only arm. The allocation sequence will be generated by the trial statistician using a code with block permutation. The participant will remain free to withdraw at any time from the trial without giving reasons and without prejudicing her further treatment. Biological samples, including blood, saliva, urine, stool, vaginal swab, and intestinal luminal contents through CapScan. CapScan is a non-invasive device (capsule) that collects gastrointestinal samples along the gastrointestinal tract following ingestion and passes into the stool.\n\nOutcome measures\u002Fvariables: The primary endpoint is the change in the mean count in the number of 11 selected fecal bacterial pathogen groups present between baseline and 2 weeks after completion of the 14-day course with Placebo or VE818 (Study arms 2 and 3), which corresponds to the 35th day, +2 from the first dose of oral vancomycin.\n\nThe 11 enteropathogen targets will be detected by customized real-time quantitative PCR-based TaqMan Array Cards (TAC-qPCR) and include the following organisms: Aeromonas, Campylobacter coli, Campylobacter jejuni, Campylobacter Pan, Enteroaggregative Escherichia coli (E. coli), Enteropathogenic E. coli, Enterotoxigenic E. coli, Plesiomonas, Shigella\\_Enteroinvasive E. coli (EIEC), Salmonella, and Klebsiella pneumoniae",[501,91],"Environmental Enteric Dysfunction (EED)",[503,200,504,505,506,507,442,508,509,510],"probiotic","pregnant women","capscan device","urine LR","VE818","malnourished children","biomarkers","EED","2025-09-26",{"date":513,"type":43},"2025-10-06",{"date":152,"type":43},{"date":377,"type":22},{"name":49,"class":50},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":18,"sex":19,"minAge":59,"maxAge":524,"enrollmentInfo":525,"targetDuration":4,"studyType":23,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":51},"100599395","ultrasound-guided-supraclavicular-block-with-vs-without-pns-100599395","NCT07083934","Ultrasound-Guided Supraclavicular Block With vs Without PNS","Comparison of Ultrasound Guided Supraclavicular Brachial Plexus Block With and Without Peripheral Nerve Stimulation (PNS) Guidance: A Randomized Controlled Tria","Inclusion Criteria:\n\n* Aged 18 years and older\n* ASA physical status I to IV\n* No contraindications to regional anaesthesia\n* Operative site located at the mid to lower arm, including the elbow, forearm, wrist, or hand\n* Ability to provide informed consent\n* Ability to reliably report symptoms to the research team related to regional anaesthesia\n\nExclusion Criteria:\n\n* Patient's refusal to participate.\n* Inability to provide first-party consent due to cognitive impairment.\n* Cognitive dysfunction which can lead to difficulties in communication and cooperation of patient.\n* Preexisting neuropathy.\n* Preexisting coagulopathy.\n* Patients who will be shifted to ICU due to post - operative ventilatory support.","80 Years",{"count":526,"type":22},44,[25],"Peripheral Nerve Blockade (PNB) became reliable with the advent of Ultrasound (US) and Peripheral Nerve Stimulation (PNS).\n\nUS offers real-time visualization but has limitations, especially with deep or obscured nerves.\n\nPNS complements US by confirming nerve proximity through motor responses. Combining both may enhance safety and success of nerve blocks. This study compares US-guided blocks with and without PNS in a randomized trial.",[530,531,532],"Supraclavicular Plexus Block","Ultrasound","Anaesthesia","2025-07-22",{"date":535,"type":43},"2025-07-24",{"date":537,"type":22},"2025-09-01",{"date":539,"type":22},"2026-01-31",{"name":49,"class":50},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":18,"sex":185,"minAge":59,"maxAge":186,"enrollmentInfo":548,"targetDuration":4,"studyType":23,"phases":550,"briefSummary":552,"conditions":553,"keywords":555,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":565,"locationsCount":51},"100519576","phase-1-efficacy-of-injectable-vitamin-d-supplementation-in-females-with-polycystic-ovary-syndrome-100519576","NCT06045351","Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome","Efficacy of Vitamin D Supplementation in Females With Polycystic Ovary Syndrome: a Randomized Open Label Delayed-start Design","Inclusion Criteria:\n\n* Recently diagnosed PCOS with presence of at least 2 of these 3 elements: clinical or biochemical signs of hyperandrogenism, chronic anovulation and polycystic ovaries (1) (from reports of available routine TVS), with VDD serum levels VD \\\u003C20 ng\u002Fml(10), age range 18- 45 years, from all ethnic background will be included.\n\nExclusion Criteria:\n\n* : Exclusion of subjects will be done by the Co-Principal Investigators (Co-PI) after history, examination and complete evaluation in the respective clinics. All female subjects meeting any of the following criteria will be excluded from the study\n\n  * Pregnancy\n  * Hypercalcemia (plasma calcium concentrations\\> 2.65 mmol\u002FL)\n  * Tuberculosis or other granulomatous disorders\n  * Chronic liver disease or alanine transaminase (ALT) level 3 times higher than the normal limit, chronic\n  * Kidney disease or serum creatinine \\>2.0 mg\u002FdL,\n  * Drug Therapies: VD replacement ; participants who had received VD injection in the last 3 months prior to recruitment in the study, oral contraceptives, hormonal replacement therapy, glucocorticoids, calcium supplementation, insulin-sensitizing drugs (incretin mimetic drugs, thiazolidinedione, sulfonylurea), lipid-lowering drugs or other drugs affecting insulin sensitivity or serum androgens (e.g., niacin, corticosteroids, beta-blockers, calcium channel blockers, thiazide diuretics), anti-epileptics, anti-retroviral, cholestyramine, anti-fungal, statins, H2 blockers, immunosuppressant, chemotherapeutic agents, antimicrobials (Rifampicin, Isoniazid, Hydroxychloroquine) or any other drug modifying lipid metabolism in the previous 3 months prior to study\n  * Suffering from congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumors, type 2 Diabetes Mellitus, renal, hepatic or thyroid disorders, hyperparathyroidism, malabsorption syndromes, Chronic Kidney Disease, Hepatic failure, cystic fibrosis, vaginal bleeding of unknown etiology or \u002Fand suffering from COVID-19 (within 3 months).",{"count":549,"type":22},142,[551],"PHASE1","Poly cystic Ovarian Syndrome (PCOS) is an endocrine disorder of reproductive age defined by \"the presence of any two out of three criteria: oligo and\u002For anovulation, excess androgen activity and\u002For polycystic ovarian morphology on ultrasound\". Considering role of vitamin D (VD) (3, 4) and high prevalence (58%) of deficiency in PCOS of Pakistan. Researchers hypothesized that its correction would improve response to standard PCOS treatment. The objective is to compare PCOS parameters in intervention group (Group A) receiving VD supplementation and then PCOS care with control group (Group B) receiving standard PCOS care and then VD supplementation. A randomized open label trial: delayed-start design will be conducted on VD deficient PCOS females VD \\\u003C 20ng\u002Fml ; Group A will receive VD injections 600,000 I.U I\u002FM once with 1 gram calcium supplement daily in the initial 12 weeks. After that standard PCOS care; i) Glucophage XR 750 mg (once for 15 days then twice daily) ii) progesterone supplementation (1 capsule Progeffik 100 mg every 3 weeks, then 1 week off) and iii) calcium supplements will be given for next 12 weeks. PCOS females in Group B will receive standard PCOS care (same) with addition of VD and calcium supplementation after 12 weeks till study end point. Study outcomes will be comparison of i) hyperandrogenism by Free Androgen Index \\[Total Testosterone, Steroid Hormone Binding Globulin ii) insulin Resistance by HOMA-IR (serum Insulin, Fasting Blood Glucose) and iii) oxidative stress by Total Antioxidant Capacity after 24-weeks in these Groups'd levels after supplementation will be assessed for confirmation of correction and calcium and albumin levels for detection of hypercalcemia. Results of this study will inform the clinicians to add VD before or after the standard PCOS care for rectification of endocrine and metabolic derangements as a cost-effective treatment and prevention strategy in these females.",[554],"Anovulatory Infertility",[556,557,558,442],"Poly cystic Ovarian Syndrome","randomized open label trial; delayed-start design","vitamin D","2025-02-17",{"date":561,"type":43},"2025-02-18",{"date":563,"type":43},"2024-01-01",{"date":377,"type":22},{"name":49,"class":50},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":18,"sex":19,"minAge":59,"maxAge":573,"enrollmentInfo":574,"targetDuration":4,"studyType":23,"phases":575,"briefSummary":576,"conditions":577,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":106},"100361717","phase-2-vitamin-d-and-polycystic-ovarian-syndrome-pcos-100361717","NCT03989778","Vitamin D and Polycystic Ovarian Syndrome (PCOS)","Efficacy of Vitamin D Supplementation and Metformin Compared to Metformin Alone for Improvement in Follicle Size of Infertile Females With Polycystic Ovary Syndrome: a Randomized Open Label Trial","Inclusion Criteria:\n\n* Females with age range 18- 36 years, from all ethnic background having primary infertility with diagnosis of PCOS when at least 2 of these 3 elements are present: hyperandrogenism, chronic anovulation and polycystic ovaries and Vitamin D deficiency serum levels \\\u003C 25 nmol\u002FL\n\nExclusion Criteria:\n\nexclusion criteria at baseline will be excluded from the study\n\n* Females with secondary Infertility\n* Hypercalcemia (plasma calcium concentrations\\> 2.65 mmol\u002FL)\n* Exclude women with Tuberculosis or other granulomatous disorders.\n* Women receiving vitamin D replacement, oral contraceptives, hormonal replacement therapy, glucocorticoids, calcium supplementation, insulin-sensitizing drugs(incretin mimetic drugs, thiazolidinedione, sulfonylurea), lipid-lowering drugs or other drugs affecting insulin sensitivity or serum androgens (e.g., niacin, corticosteroids, beta-blockers, calcium channel blockers, thiazide diuretics), anti-epileptics, anti-retroviral, cholestyramine, anti-fungal, statins, H2 blockers, immunosuppressants, chemotherapeutic agents, antimicrobials (Rifampicin, isoniazid, hydroqychloroquin) or any other drug modifying lipid metabolism in the previous 3 months prior to study\n* Women with congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumors, type 2 diabetes mellitus, renal, hepatic or thyroid disorders, hyperparathyroidism, malabsorption syndromes, Chronic Kidney Disease Hepatic failure, cystic fibrosis, vaginal bleeding of unknown etiology Women Those who had Bariatric surgery will also be excluded.","36 Years",{"count":293,"type":22},[498],"Primary Objectives:\n\nTo evaluate the efficacy of metformin and Vitamin D supplementation on serum insulin and serum androgen levels (Total testosterone, Steroid Hormone Binding Globulin, Free Androgen Index) levels compared metformin alone in infertile Poly cystic ovarian females of reproductive age group.\n\nSecondary Objectives:\n\nTo measure change in endometrial thickness\u002Fnumber of follicles and follicular size by day 12 trans-vaginal ultrasound in the intervention group i.e. combination of metformin and vitamin D supplementation",[578,579,580],"Infertility, Female","Infertility","Vitamin D Deficiency",{"date":582,"type":43},"2025-02-19",{"date":584,"type":43},"2023-02-01",{"date":586,"type":22},"2025-07-13",{"name":49,"class":50},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":18,"sex":185,"minAge":59,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":23,"phases":597,"briefSummary":598,"conditions":599,"keywords":601,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":51},"100566273","dural-puncture-epidural-vs-standard-epidural-technique-in-parturient-receiving-continuous-labour-epidural-infusion-100566273","NCT06653036","Dural Puncture Epidural Vs Standard Epidural Technique in Parturient Receiving Continuous Labour Epidural Infusion","Dural Puncture Epidural Vs Standard Epidural Technique in Parturient Receiving Continuous Labour Epidural Infusion: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Nulliparous \u002F Multiparous women\n* Age \\>18 years\n* ASA 1 \\& 2\n* Singleton vertex presentation\n* Gestational age 37-42 weeks\n* Parturient with established labor and pain score ≥ 3\n\nExclusion Criteria:\n\n* Major cardiac disease\n* History of chronic pain\n* Chronic opioid user\n* Platelet count \\\u003C 70 x 109\u002FL\n* spinal cord anomalies\n* Use of anticoagulants\n* Allergic to local anesthetics\n* Patients with preeclampsia\u002F eclampsia\n* Known fetal anomalies",{"count":596,"type":22},38,[25],"The goal of this study is to evaluate the quality and safety of labor analgesia by comparing the use of Dural puncture epidural technique to Standard epidural technique while maintaining labor analgesia by means of continuous epidural infusion in parturient. The main questions it aims to answer are\n\n* Effectiveness and quality of labor analgesia\n* Frequency of catheter adjustments\n* Need for catheter replacements\n* Incidence of failed regional anesthesia requiring conversion to general anesthesia",[600],"Quality Health Care",[602,603],"Quality Labor Analgesia","Maternal Adverse Events","2025-01-28",{"date":606,"type":43},"2025-01-30",{"date":608,"type":43},"2024-11-28",{"date":610,"type":22},"2025-12-31",{"name":49,"class":50},{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":18,"sex":19,"minAge":619,"maxAge":620,"enrollmentInfo":621,"targetDuration":4,"studyType":23,"phases":622,"briefSummary":623,"conditions":624,"keywords":630,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":641,"locationsCount":106},"100575866","mainstreaming-a-life-skills-education-programme-right-to-play--plus-to-reduce-violence-against-girls-in-pakistan-100575866","NCT06777849","Mainstreaming a Life Skills Education Programme Right to Play- Plus to Reduce Violence Against Girls in Pakistan","RTP-Plus","Inclusion Criteria:\n\n* Schools will be chosen from District Malir and adjacent areas, including Korangi and East Karachi. Among the 100 selected schools, the following distribution will be maintained: 40 girls-only schools (public), 40 co-ed schools (private), and 20 boys-only schools (public).\n* Schools having a minimum of 30 students enrolled in grade 6\n* Private schools with low to medium fees, with monthly amounts ranging from PKR 2000 to 3500.\n* Factors such as teacher availability, school management support, accessibility to research and intervention partners, and school clustering will also be considered for the selection of these hundred schools.\n* Schools' willingness to adapt child protection and safeguarding\u002Fanti-harassment administrative measures and policies to improve school safety, reduce the use of corporal punishment, enhance school performance, and increase girls' retention rates, primarily apply to private schools.\n\nExclusion Criteria:\n\n* Schools where Right to Play or Aahung have already implemented their play-based\u002Fother activities.","10 Years","16 Years",{"count":463,"type":22},[25],"Right to Play-Plus (RTP-Plus) aims to address violence against women and girls by promoting changes in social norms among young people within the school environment. The project focuses on building the capacity of young people to identify harmful gender norms and prevent violence against girls and boys by incorporating Right to Play's play-based learning methodology and Aahung's Life Skills Based Education curriculum. The strategies employed include interactive, learner-centered methodologies, curricular activities, and the development of peer educators and junior leaders. Teachers play a crucial role as key influencers and delivery agents of the curricular content. The project emphasizes capacity development for teachers, challenging their social norms, strengthening their play-based methodologies, and improving their sexual and reproductive health and rights knowledge (SRHR). The ultimate goal is to equip teachers to effectively deliver a gender transformative curriculum, empowering young people to respond to and prevent violence.\n\nThe research question for this study is:\n\nWhat is the effectiveness of an adapted play-based life skills education that incorporates a \"whole school\" approach in reducing sexual harassment and abuse, peer violence experiences, mental illness (including suicidal ideation), improving resilience, and promoting gender equity, SRHR knowledge in both home and public settings?\n\nThe research objective will be achieved through two-arm cluster randomized controlled trial (for girls-only, co-ed, and boys-only schools). The intervention arm participants will be able to participate in the adapted play-based life skills education intervention, which the Right to Play and Aahung will deliver. It will be provided to all eligible school children in grade 6. Moreover, a delayed intervention will be offered to the control arm upon completion of endline data collection after the comprehensive intervention is delivered in the intervention arm.",[625,626,627,628,629],"Mental Health","Gender Based Violence","Resilience","Gender Equity","Sexual and Reproductive Health and Rights",[631,632,633,634],"GBV","adolescent health","play-based life skills","what works","2025-01-15",{"date":637,"type":43},"2025-01-17",{"date":639,"type":43},"2024-12-18",{"date":236,"type":22},{"name":49,"class":50},{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":4,"eligibilityCriteria":648,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":649,"targetDuration":4,"studyType":23,"phases":651,"briefSummary":652,"conditions":653,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":665},"100567946","school-based-e-health-non-communicable-disease-ncd-prevention-program-100567946","NCT06674798","School-based e-Health Non-Communicable Disease (NCD) Prevention Program","School-based e-Health Non-Communicable Disease (NCD) Prevention Program to Improve Awareness in Adolescents From Urban Pakistan","Inclusion Criteria:\n\nPhase 1 (FGDs and Interviews)\n\n* Students currently enrolled in secondary and higher secondary schools in Karachi and are in grades 9 to 12.\n* Teachers who have been employed in secondary and higher secondary schools in Karachi for a minimum duration of 6 months.\n* Parents or legal guardians of students who are currently enrolled in secondary and higher secondary schools in Karachi.\n* Principals and vice principals of secondary and higher secondary schools in Karachi, District Education Officers, and decision-makers at Provincial Department of Education.\n\nPhase 2 (Intervention)\n\n\\- Both study and control group would be selected from secondary schools (students in grades 9-10) and Higher Secondary Schools (students in grades 11-12) located in Karachi, Pakistan\n\nPhase 3 (FGDs) - Participants from grades 9 to 12 of the secondary and higher secondary schools who actively participated in the intervention and attended all the health-promoting sessions (equal representation of male and female)\n\nExclusion Criteria:\n\n\\- Schools outside Karachi",{"count":650,"type":22},272,[25],"The goal of this sequential mixed method study is to assess the feasibility and effectiveness of a school-based eHealth-NCD prevention program intervention to improve adolescents' knowledge, attitude, and practices regarding NCDs and associated risk factors. It aims :\n\n1. To identify barriers and facilitators associated with implementing a school-based eHealth intervention to improve the knowledge, attitudes, and practices of secondary and higher secondary school students in Pakistan regarding NCDs and their associated risk factors.\n2. To explore the stakeholders' perceptions regarding the design and content of the School based eHealth NCD prevention Program to improve the knowledge, attitudes, and practices of secondary and higher secondary school students in Pakistan regarding NCDs and their associated risk factors.\n3. To assess the feasibility and effectiveness of the School-based eHealth NCD prevention program in secondary and higher secondary school in Karachi.\n4. To evaluate the effectiveness of the school-based eHealth NCD prevention program in significantly improving the knowledge, attitudes, and practices of secondary and higher secondary school students in Karachi, Pakistan, regarding NCDs and their associated risk factors, as compared to a control group not receiving the intervention.\n5. To explore the perceptions of students regarding the usefulness acceptability and task technology fit of the School-based eHealth NCD prevention Program in improving the knowledge, attitude, and practices of Pakistani Higher Secondary School students regarding NCDs and their associated risk factors.\n\nResearcher aim to evaluate the effectiveness of the school-based eHealth NCD prevention program in significantly improving the knowledge, attitudes, and practices of secondary and higher secondary school students in Karachi, Pakistan, regarding NCDs and their associated risk factors, as compared to a control group not receiving the intervention.\n\nParticipants of intervention group will attend health-promoting sessions delivered by trained facilitators, with each session lasting 30 to 40 minutes. There will be a total of six health-promoting sessions be focused on the leading risk factors associated with NCDs as reported by different studies such as physical inactivity, unhealthy diet and overweight, obesity, harmful alcohol consumption and tobacco use will be conducted in the classroom for the intervention group.",[654,655,656],"Noncommunicable Diseases","Health Knowledge, Attitudes, Practice","Non-communicable Disease Risk Factors","2024-11-04",{"date":659,"type":43},"2024-11-05",{"date":661,"type":43},"2024-03-01",{"date":663,"type":22},"2025-03",{"name":49,"class":50},7,{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":671,"acronym":4,"eligibilityCriteria":672,"healthyVolunteers":12,"sex":185,"minAge":4,"maxAge":4,"enrollmentInfo":673,"targetDuration":4,"studyType":23,"phases":675,"briefSummary":676,"conditions":677,"keywords":679,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":682,"lastUpdatePostDateStruct":683,"startDateStruct":685,"completionDateStruct":687,"leadSponsor":689,"locationsCount":106},"100560062","ecd-newborn-parenting-education-program-100560062","NCT06572254","ECD Newborn Parenting Education Program","Early Childhood Newborn Parenting Education Program at Primary Health Care Facilities of Pakistan: A Feasibility Study","Inclusion Criteria:\n\n1. Normal delivery\n2. No underlying morbidities of the newborn\n3. Are not living in ultra-poverty less than 15000\u002F- total household income.\n\nExclusion Criteria:\n\n1. Newborn or mother with underlying conditions or morbidities\n2. Living under 15000 per month",{"count":674,"type":22},400,[25],"Early childhood development: specifically the first 1000 days of life are of crucial importance. It sets the trajectory for the future and transgenerational health. Life of a neonate is influenced by several factors of which responsive caregiving is one of the most imperative facets. In the earliest days of life, the role of responsive caregiving is vital for the child's growing brain. Interactions between the primary caregiver and the neonate in early infancy period foster social and cognitive growth, build trust, provide sense of security, and helps build brain of the young child. In resource constraints areas, particularly in primary health care settings, there is a lack of initiatives to support responsive caregiving. The investigators intend to do an implementation adaptation and assessment of impact and efficacy of early childhood newborn parenting education program at primary health care facilities of Pakistan and Afghanistan. Investigators already have a structured program at our tertiary health care setting, with this project, investigators now intend to adapt it to primary care settings of Aga Khan Health Services Pakistan and Afghanistan a) explore the impact of newborn parenting education program on parental outcomes b) conduct training for health care providers and asses their pre-post knowledge and skills and c) explore systems readiness to scale up this program at national level. The expected outcome of this research is to build a proof of concept of this intervention in primary healthcare settings and disseminate its findings for a national level scale up and to advocate the importance of it to the government sector, civil society organization and funding agencies.",[678],"Parenting",[680,681,678],"Early childhood development","Responsive caregiving","2024-08-26",{"date":684,"type":43},"2024-08-27",{"date":686,"type":43},"2023-01-01",{"date":688,"type":22},"2025-03-31",{"name":49,"class":50},{"id":691,"slug":692,"hasResults":12,"nctId":693,"briefTitle":694,"officialTitle":695,"acronym":4,"eligibilityCriteria":696,"healthyVolunteers":12,"sex":19,"minAge":697,"maxAge":59,"enrollmentInfo":698,"targetDuration":4,"studyType":23,"phases":700,"briefSummary":701,"conditions":702,"keywords":705,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":707,"lastUpdatePostDateStruct":708,"startDateStruct":710,"completionDateStruct":712,"leadSponsor":714,"locationsCount":51},"100510499","phase-4-effect-of-methylprednisolone-on-systemic-inflammatory-response-during-pediatric-congenital-open-heart-surgery-100510499","NCT05927233","Effect of Methylprednisolone on Systemic Inflammatory Response During Pediatric Congenital Open-Heart Surgery","Effect of Methylprednisolone on Systemic Inflammatory Response and Clinical Parameters During Pediatric Congenital Open-Heart Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children 1 month- 18 years of age\n* Undergoing Cardiac surgery for the first time and requiring CPB\n* Surgeries for both cyatonic and acyanotic heart disease\n\nExclusion Criteria:\n\n* Pre-mature babies (\\\u003C 28 weeks at birth)\n* Neonates\n* Prior cardiac requiring CPB\n* Surgeries requiring CPB \\> 6 hours\n* Surgeries requiring second run of CPB\n* Patients requiring additional steroids during first 24 hours of CICU stay\n* Patient expires within the initial 24 hours CICU stay.\n* Compromised immune system - that is, known immunodeficiency or use of\n* immunomodulatory therapy.\n* Peri-operative presence of two or more clinical or laboratory signs of active infection that were not attributable to any other cause: fever more than 100°F, heart rate or respiratory rate more than the normal range for age, white blood cell count more than 15% of the upper limit of normal, and an elevated C-reactive protein level above baseline.\n* Preoperative mechanical ventilation, and preoperative need of inotropic agents or mechanical circulatory support.\n* Patient already receiving steroids","1 Month",{"count":699,"type":22},60,[219],"The goal of this study is to evaluate the effects of steroids on the early postoperative inflammatory response in patients undergoing elective pediatric congenital cardiac surgery, requiring cardiopulmonary bypass (CPB).",[703,704],"Cyanotic Heart Disease","Cardiopulmonary Bypass",[706],"Paediatric population","2024-07-30",{"date":709,"type":43},"2024-07-31",{"date":711,"type":43},"2023-04-01",{"date":713,"type":22},"2025-06-30",{"name":49,"class":50},""]